drugset / Trial / NCT00096304

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00096304

Phase 1 Terminated 36 enrolled Medical University of South Carolina
Treatment

Summary

RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.

Timeline

Start
2004-06-08
Primary completion
2006-09-06
Completion
2007-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule
Background Docetaxel Small molecule

Indications